



# Where to identify information on adverse effects for a systematic review

Su Golder<sup>1</sup>, Yoon Loke<sup>2</sup>, Jane Burch<sup>1</sup>

<sup>1</sup> Centre for Reviews and Dissemination, University of York (spg3@york.ac.uk); <sup>2</sup> School of Medicine, University of East Anglia, Norwich

## Introduction

Ideally systematic reviews of effects should include information about adverse effects. Where information on adverse effects is sought will influence the amount and type of data retrieved.<sup>1</sup>

Data on adverse drug effects can potentially come from many different sources. However, little is known about the relative value of these sources.

## Objectives

To examine how issues beyond test accuracy have been considered in published diagnostic systematic reviews. To discuss our own experience in conducting these reviews and assess whether a restriction to test accuracy studies would have changed findings.

## Aim

To investigate the utility of searching different data sources to identify information on adverse effects of health care interventions.

## Methods

We conducted a systematic review of methodological research which compared at least two sources to identify information on adverse effects. Searches were undertaken in 10 databases and supplemented with other sources of information such as handsearching, citation searching and contacting experts. Two reviewers screened the records for potentially relevant papers.

## Results

### Included studies

- 18 methodological evaluations met the inclusion criteria<sup>2-19</sup>
- 16 evaluated sources of data on the adverse effects of drug interventions
- The number of sources included in each study varied between 2 and 24
- The majority of the methodological evaluations compared the different sources of data using the numbers of relevant references retrieved, however, 4 used scores for ability to answer queries on adverse effects<sup>2, 4, 7, 9</sup>

### Methodological assessment

The generalisability of the methodological evaluations was limited by the number of relevant references, the limited range of interventions and adverse effects included and because many of the evaluations were done over 20 years. The number of unique and total references was described fully for four studies<sup>3, 10, 13, 15</sup> and partially for five studies.<sup>5, 11, 12, 17, 19</sup> The sensitivity, precision, search functionality, the difference between the availability and the identification of studies, cost, quality of records or impact on research of searching the databases was rarely considered.

### Database comparisons

- 8 methodological evaluations found that searching EMBASE retrieves more relevant references than MEDLINE<sup>3, 5, 6, 11, 12, 15, 17, 19</sup>
- 2 methodological evaluations (both of non-pharmaceutical drugs) found that MEDLINE retrieved more records than EMBASE<sup>8, 19</sup>
- 3 of the 4 methodological evaluations which included Derwent Drug File indicated its potential value above that of EMBASE and MEDLINE<sup>5, 11, 15</sup>
- 3 of the 4 methodological evaluations which included TOXLINE found that MEDLINE and EMBASE retrieved more relevant references than TOXLINE
- 5 of the 6 methodological evaluations which included International Pharmaceutical Abstracts (IPA)<sup>6, 8, 10, 12, 16, 18</sup> indicated that IPA retrieves either the lowest or joint lowest number of relevant references

### Non-database comparisons

- Other sources also retrieved relevant references, particularly, manufacturers, reference books, reference lists/hand searching and AltaVista

## Unique references

- Only one database, BIOSIS, did not identify any unique references and this was only in one case study<sup>15</sup>

## Discussion

It is not surprising that searches in EMBASE tended to retrieve the most records for adverse drug effects as EMBASE is a large pharmacological and biomedical bibliographic database renowned for its drug-related literature. The relative value of Derwent Drug File over EMBASE and MEDLINE merits further analysis. There are many other potentially useful sources of data not covered in these studies including, full-text databases, post-marketing surveillance databases, regulatory agencies (such as the FDA), citation searching and discussion lists.

## Conclusion

This review indicates the value of searching a range of sources when conducting a thorough search for information on adverse effects and that of the included sources EMBASE, Derwent Drug File, MEDLINE, Industry, Iowa Drug Information Service (IDIS), and drug monographs may provide the greatest number of references for adverse effects information.

An evaluation of a significant number of sources using a large set of references with a range of types of adverse effects would be useful to prioritise the sources available for data on adverse effects.

## References

1. Ioannidis JP, Mulrow CD, Goodman SN. Adverse events: the more you search, the more you find. *Ann Intern Med* 2006;144:298-300.
2. Clauson KA, Polen HH, Marsh WA. Clinical decision support tools: Performance of personal digital assistant versus online drug information databases. *Pharmacotherapy* 2007;27:1651-8.
3. Golder S, McIntosh HM, Duffy S, Glanville J. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. *Health Inf Libr J* 2006;23:3-12.
4. Kahn A, Joseph A. A comparison to the Micromedex and Lexi-Comp medicines information databases. Harold Wood MIC, BHR Hospitals NHS Trust; 2004. [cited 2008 15 May]. Available from: <http://www.ukmi.nhs.uk/activities/clinicalGovernance/default.asp?pageRef=4>.
5. Thomson Scientific. *Derwent Drug File: Definitive drug journal and conference information*. 2004. [cited 2008 15 May] Available from: <http://scientific.thomson.com/media/dw/productpdfs/ddf-compare.pdf>.
6. Bagnall AM, Jones L, Glanville J, Kleijnen J. Assessing adverse events in a systematic review of atypical antipsychotics for schizophrenia. *4th Symposium on Systematic Reviews: Pushing the Boundaries*, July 2002 in Oxford.
7. Walker JB. Evaluation of the ability of seven herbal resources to answer questions about herbal products asked in drug information centers. *Pharmacotherapy* 2002;22:1611-5.
8. Stone VL, Fishman DL, Frese DB. Searching online and Web-based resources for information on natural products used as drugs. *Bull Med Libr Assoc* 1998;86:523-7.
9. Belgado BS, Hatton RC, Doering PL. Evaluation of electronic drug information resources for answering questions received by decentralized pharmacists. *Am J Health Syst Pharm* 1997;54:2592-96.
10. Fishman DL, Stone VL, DiPaula BA. Where should the pharmacy researcher look first? comparing International Pharmaceutical Abstracts and MEDLINE. *Bull Med Libr Assoc* 1996;84:402-8.
11. Sodha RV, Van Amelsvoort T. Multi-database searches in biomedicine: citation duplication and novelty assessment using carbamazepine as an example. *J Inf Sci* 1994;20:139-41.
12. Biarez O, Sarrut B, Doreau CG, Etienne J. Comparison and evaluation of nine bibliographic databases concerning adverse drug reactions. *Discp: Ann Pharmacother* 1991;25:1062-65.
13. Haramburu F. Manual versus computer-based literature searches for adverse drug reactions. *The Annals of Pharmacotherapy* 1991;25:215-16.
14. Roush MK, McNutt RA, Flint Gray T. The adverse effect dilemma: quest for accessible information. *Ann Intern Med* 1991;114:298-99.
15. Van Putte N. A comparison of four biomedical databases for the retrieval of drug literature. *Health Inf Lib* 1991;3:119-27.
16. Al Hefzi A, Catania PN, Mergener MA, Lum BL. Evaluation of three manual drug information retrieval systems for investigational antineoplastic drugs. *Drug Intell Clin Pharm* 1987;21:196-200.
17. Madden M, MacDonald A. An evaluation and comparison of nine drug information retrieval services. *Drug Inf J* 1977;11:47-59.
18. Tourville JF, McLeod DC. Comparison of the clinical utility of four drug information services. *Am J Hosp Pharm* 1975;32:1153-8.
19. Verheijen-Voogd C, Mathijssen A. A contribution to the comparison of the usefulness of the data bases of Excerpta Medica and MEDLARS in biomedical literature retrieval. *Aslib Proc* 1974;26:136-51.

CRD is part of the National Institute for Health Research and is a department of the University of York. The views expressed in this poster are those of the authors alone.

